NPS Pharmaceuticals, Inc. (NASDAQ:NPSP)
CAPS Rating:
A biopharmaceutical company focused on the development and commercialization of small molecule drugs and recombinant proteins.
The World's Greatest Investing Community
A biopharmaceutical company focused on the development and commercialization of small molecule drugs and recombinant proteins.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
I'm back as promised to throw down a new red thumb on NPS, who have inexplicably managed to increase their market cap over 200M despite having a terrible pipeline and no positive catalysts whatsoever that I can determine. Mentions of Preos have completely disappeared from the quarterly statements, and I am at a loss to figure out what has happened to their phase III trial which should have completed enrollment months ago. The Gattex trial had a lousy result and the new phase III trial hasn't begun yet. There are very few companies this lousy which have managed to escape the biotech sector decline (Nymox comes to mind), so it seems like their days must be numbered.